No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
COO240517C95000
- 1.40
- +0.75+115.38%
15min DelayClose May 14 15:59 ET
3.00High0.85Low
0.85Open0.65Pre Close237 Volume552 Open Interest95.00Strike Price41.53KTurnover32.91%IV0.82%PremiumMay 17, 2024Expiry Date0.96Intrinsic Value100Multiplier3DDays to Expiry0.44Time Value100Contract SizeAmericanOptions Type0.6386Delta0.1259Gamma54.83Leverage Ratio-0.1946Theta0.0053Rho35.02Eff Leverage0.0339Vega
Intraday
- 5D
- 1D
News
CooperCompanies to Participate in the William Blair Growth Stock Conference
SAN RAMON, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, will participate in the William Blair Growth Stock Conference on Wednesday, June 5, 2024. Dan
Cooper Companies (NASDAQ:COO) Will Be Hoping To Turn Its Returns On Capital Around
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increa
Express News | Cooper Companies Inc: In Connection With Entry Into Credit Agreement, Terminated Existing Revolving Credit & Term Loan Agreement, Dated April 1, 2020
Express News | Cooper Companies Inc: Unless Terminated Earlier, Revolving Credit Facility Matures on May 1, 2029
Express News | Cooper Companies Inc: Credit Agreement Provides for a Multicurrency Revolving Credit Facility in Aggregate Principal Amount of $2.300 Bln
Express News | Cooper Companies Inc: Entered Into a Revolving Credit Agreement
Comments
Investors maintain a high P/E ratio for Cooper Companies despite earnings decline, buoyed by strong forecasted growth. This is expected to continue supporting the share price.
Why Investors Shouldn't Be Surprised By The Cooper Companies, Inc.'s (NASDAQ:COO) P/E 1
Jonathan Banas, executive vice president and chief financial officer, expressed delight at the appointment of Nudd, praising her as an invaluable and energetic leader within the finance function at Cooper Standard.
Cooper Companies' decreasing ROCE and stagnant sales despite reinvestment don't suggest a potential multi-bagger. The past five-year return indicates awareness of these trends. Consider other options for a multi-bagger.
Baird advocates medtech companies such as Alcon, Stryker, and Cooper due to product and pricing strengths. Belief is strong in Alcon's 2024 margin possibilities, Stryker's premium pricing and predicted robust orthopedic demand, and projected revenue growth for Boston Scientific and Axonics.
Cooper Companies' high P/E ratio is backed by robust earnings growth outlook. Shareholders are holding onto their stocks due to the expected superior future earnings growth.
Read more